IRCT201202068943N1.

Methods	Randomised, double‐blind trial conducted at Neurology clinic of Ahvaz Golestan Hospital, Iran 2 treatment arms: OXC or PHT
Participants	Participants > 65 years with partial and secondary generalised epilepsy
Interventions	Monotherapy with PHT or OXC for 6 months Maximum dose: PHT = 600 mg/d, OXC = 600 mg/d
Outcomes	Seizure symptoms Adverse events
Notes	Trial registered as IRCT201202068943N1 on the Iranian Registry of Clinical Trials. We have attempted to contact the trial authors for more information